Pharma · Biotech · Life Sciences
Patient Insight That Shapes Better Treatments
Patient research for pharmaceutical and life sciences companies. From clinical trial design to patient support programmes, we deliver authentic patient voice that improves drug development, strengthens regulatory submissions, and centres what matters to people living with disease.
Why pharmaceutical companies work with us
Clinical trials that struggle to recruit. Patient-reported outcomes that miss what actually matters. Support programmes designed without understanding real treatment burden. Regulatory submissions that lack credible patient voice.
We help pharma, biotech, and life sciences companies understand patient experience deeply, involve patients ethically in drug development, and deliver research that regulators, payers, and clinicians trust.
Patient research services for pharma
From early-stage drug development to post-market programmes, we deliver patient insight at every phase of the lifecycle.
Clinical Trial PPI
Patient input on trial design, outcome measures, recruitment materials, consent processes, and dissemination. Early-phase through Phase III and real world studies.
Patient Journey Mapping
Understand diagnosis pathways, treatment experiences, care transitions, and support needs. Especially valuable for rare diseases and complex conditions.
Explore patient journey mappingTreatment Burden Research
Deep dive into what it's actually like to take medications, manage side effects, attend appointments, and live with disease. Reveals unmet needs.
Patient Advisory Boards
Recruit and facilitate patient panels for drug development programmes. One-off consultations or ongoing advisory roles across development lifecycle.
Patient-Reported Outcomes Development
Co-develop PRO measures with patients. Test draft instruments, validate meaningfulness, and ensure outcomes capture what matters to patients.
Caregiver & Family Research
Understand caregiver burden, family impact, and decision-making dynamics. Essential for paediatric, rare disease, and neurodegenerative conditions.
Patient Support Programme Design
Test patient support concepts, educational materials, adherence tools, and digital health solutions with target populations before launch.
Real-World Evidence Studies
Qualitative research to complement RWE data. Patient interviews, surveys, and longitudinal studies to understand treatment patterns and outcomes.
Our approach to pharma patient research
We understand drug development timelines, regulatory requirements, and confidentiality needs. Our research is designed to meet pharma standards.
Reach hard-to-reach patient communities
We work with patient organisations, specialist clinics, and condition-specific networks to reach participants who are difficult to recruit through standard panels, including rare and complex conditions, underserved communities, and clinical populations with specific treatment histories.
Ethics and governance rigour
REC approval when required. GDPR-compliant data handling. Informed consent processes. Medical review of materials. We meet pharmaceutical industry standards.
Confidentiality protocols
NDAs standard. Secure data storage. Anonymised reporting. We understand competitive sensitivity and protect commercially confidential information.
Fair patient payment
NIHR-aligned payment rates. Options that don't affect disability benefits. Expenses covered. We pay patients properly for their time and expertise.
Clinical sensitivity
Medically-informed research design. Understanding of disease progression, treatment pathways, and clinical terminology. Medical review of findings available.
Trauma-informed approaches
Sensitive handling of difficult experiences. No pressure to share traumatic details. Debrief support available. Especially important for oncology, mental health, life-limiting conditions.
Regulatory-ready outputs
Documentation suitable for regulatory submissions. Clear methodology, participant demographics, verbatim quotes, thematic analysis. Format that meets EMA, FDA, MHRA, NICE standards.
Global reach capability
UK patient research as standard. European multi-country studies available. Partnership with US research teams for FDA submissions. Multi-language recruitment and interviews.
Pharmaceutical patient research in practice
The kind of patient research that shapes better trials, stronger submissions, and more effective patient support - illustrated by the scenarios we work with
Rare disease patient journey mapping
A biotech company developing a treatment for a rare condition needs to understand the patient experience before designing its trial and support programme. Patients and caregivers are recruited through specialist clinics and patient organisations. Their diagnosis journeys, treatment burden, and unmet needs are mapped in depth.
What good looks like: Phase II endpoints that reflect what patients actually experience rather than what was easiest to measure. Regulatory strategy informed by genuine patient evidence. An orphan drug designation application that reviewers take seriously.
Clinical trial materials review
A pharmaceutical company finds that patient information sheets and consent forms for a new trial are too complex for participants to genuinely understand. Patients review and provide input on materials before finalisation.
What good looks like: Plain English materials with a visual timeline that participants can actually follow. Clear, honest risk communication. Better-informed consent. Recruitment rates that improve because participants trust what they are reading.
Patient preference and quality of life research
A company seeking approval for a more convenient dosing regimen needs evidence that reduced frequency genuinely improves quality of life for patients. Structured patient preference research quantifies what the change means in practice.
What good looks like: Payer submission data that demonstrates value beyond clinical outcomes. Evidence of what patients say matters to them, not what manufacturers assumed. A patient support programme designed around real preferences.
Patient advisory board for a clinical programme
A biotech establishing a patient advisory board for a neurodegenerative disease programme recruits patients and caregivers representing the full spectrum of disease experience. The board meets regularly over the course of the programme, providing input on trial design, endpoint selection, patient materials, and dissemination strategy.
What good looks like: Protocol amendments made before Phase III rather than during. Regulatory reviewers who note the quality of patient involvement. Patients who are genuine partners in the research rather than afterthoughts.
Who we work with in pharma
From medical affairs to clinical development, we support teams across the organisation
Pharmaceutical patient research pricing
Transparent pricing for patient insight that meets pharmaceutical industry standards
Rapid Consultation
Patient Input
Fast patient feedback for protocol review, materials testing, or regulatory submission. Quick turnaround when development timelines are tight.
- 4-6 patient/caregiver participants
- One consultation session or review round
- Targeted recruitment via patient organisations
- Key insights summary
- NDA and confidentiality protocols
- 3-4 week turnaround
In-Depth Research
Patient Insight Programme
Comprehensive patient research for journey mapping, treatment burden studies, or outcome measure development. Depth for regulatory submissions.
- 12-16 in-depth patient interviews
- Multi-country recruitment available
- Clinical literature review
- Detailed thematic analysis
- Regulatory-ready report with verbatims
- Stakeholder presentation
- 6-8 week delivery
Strategic Partnership
Patient Advisory Board
Ongoing patient advisory board for drug development programme. Recruitment, facilitation, and documentation across 12-24 month partnerships.
- Patient & caregiver advisory board setup
- Quarterly or bi-annual meetings
- Protocol and materials review
- Medical review of findings
- Impact documentation for regulatory use
- 12-24 month engagement
All packages include: Fair patient/caregiver payments (NIHR-aligned), specialist recruitment via patient organisations and clinics, NDA and confidentiality protocols, ethics review where needed, medical review of materials, secure data storage, and regulatory-ready documentation.
Rare disease uplift: Ultra-rare condition research (UK prevalence <500) typically adds 25-35% to base pricing due to recruitment complexity. International multi-country studies priced separately.
Clinical or rehabilitation populations: typically adds 30–40% to base pricing.
Procurement: We work with pharma procurement processes, SOWs, framework agreements, and standard terms. Invoicing via purchase orders. Liability insurance in place.
Common questions
What is patient research for pharmaceutical companies?
Patient research for pharma involves involving patients, caregivers, and the public in drug development, clinical trial design, and treatment programme planning. It includes patient journey mapping, treatment burden studies, patient advisory boards, PPI for clinical trials, and patient-reported outcome development. The goal is to ensure drug development reflects what actually matters to people living with the condition.
How do you recruit patients for pharmaceutical research?
We recruit through a network of patient advocacy groups, condition-specific charities, clinical networks, and community organisations across the UK. For rare conditions or complex inclusion criteria, we work with specialist networks to access hard-to-reach patient communities.
Can you support clinical trial PPI requirements?
Yes. We provide PPI services that meet NIHR and research ethics requirements for clinical trials, including documented patient involvement in trial design, plain language summary review, and patient advisory input at key development milestones.
How much does pharmaceutical patient research cost?
Rapid patient consultation projects start from £10,000. In-depth patient insight programmes, including patient journey mapping or multi-session advisory board work, start from £16,000. Costs include patient recruitment, fair incentive payments, facilitation, analysis, and a written report.
How do you handle ethics and consent for patient research?
We follow established research ethics principles including informed consent, data protection, and fair payment for participants. For studies requiring formal ethics review, we advise on the process and can support ethics submissions. All patient involvement work meets the standards that regulatory bodies and clinical research governance frameworks expect.
We fully recognise the effort your team invested in recruitment, moderation, and analysis, and we genuinely appreciate the quality of the discussions and reporting.
- Usability problems in an insulin device surfaced before manufacturing locked anything in, with human factors evidence supporting the regulatory submission.
- An NHS patient portal team got a prioritised, evidenced list of adoption barriers, and the highest-leverage fix wasn't the one they expected.
- Patient involvement changed a trial's primary endpoint before the protocol was finalised, cited by the ethics committee as a model for evidencing PPIE.
Trusted PPI and PPIE delivery partner to the NIHR HealthTech Research Centre in Accelerated Surgical Care.
Ready to talk it through?
If you want to talk through options, share a brief, or sanity check an approach, head to our contact page and we will come back to you within one working day.
Contact usWe usually respond within one working day. Want a number first? Build a ballpark estimate - no email required.
Prefer to talk it through first?
Book a free 20-minute call. No obligation, no sales pitch. We'll tell you honestly whether research is worth it for your decision, and what it would cost.